Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.59
+0.14000.37%
Post-market: 37.590.00000.00%19:30 EDT
Volume:429.25K
Turnover:16.16M
Market Cap:3.62B
PE:-19.22
High:38.27
Open:37.74
Low:37.24
Close:37.45
52wk High:42.68
52wk Low:24.24
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.75
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.02
PE(LYR):-29.25

Loading ...

Ideaya Biosciences Announces Clinical Collaboration with Genentech in Mtap-Deleted Kras G12d-Mutant Pancreatic Cancer

THOMSON REUTERS
·
Aug 19

Ideaya Biosciences - Co and Genentech Retain All Commercial Rights to Their Compounds

THOMSON REUTERS
·
Aug 19

Ideaya Biosciences, - Genentech to Sponsor Clinical Trial with Joint Governance

THOMSON REUTERS
·
Aug 19

LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 08

Ideaya Biosciences price target lowered to $42 from $45 at Citizens

TIPRANKS
·
Aug 07

IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

TIPRANKS
·
Aug 06

Ideaya Biosciences, Inc. : Leerink Partners Cuts Target Price to $31 from $37

THOMSON REUTERS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction

Simply Wall St.
·
Aug 05

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)

TIPRANKS
·
Aug 05

Wedbush Adjusts Price Target on IDEAYA Biosciences to $60 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 04

Ideaya Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q2 Net Loss $1.22 a Share, vs. FactSet Est of $1.18 Loss

MT Newswires Live
·
Aug 04

IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate

Benzinga Earnings
·
Aug 04

Ideaya Q2 FY26 Net Loss Widens to $112.45 Million; Revenue Rises 35.02% to $8.86 Million vs Q1 FY26

Reuters
·
Aug 04

Ideaya Biosciences Q2 Operating Expenses USD 131.148 Million

THOMSON REUTERS
·
Aug 04

Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 04

Ideaya Biosciences Grants 260,200 Inducement Stock Options at $36.4 Per Share

Reuters
·
Jul 31

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 31

Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?

Simply Wall St.
·
Jul 30